In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-LactamSusceptible Escherichia coli

被引：11

作者：

Monogue, M. L. ^{[1
]}

Nicolau, D. P. ^{[1
,2
]}

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06115 USA

[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06115 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 12期

关键词：

KLEBSIELLA-PNEUMONIAE; PSEUDOMONAS-AERUGINOSA; PHARMACODYNAMIC MODEL; PROLONGED-INFUSION; CARBAPENEMASE; THERAPY; ANTIMICROBIALS; CEFTAZIDIME; AVIBACTAM; PROFILE;

D O I：

10.1128/AAC.01208-16

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Recent findings have identified Escherichia coli strains that are pan-beta-lactam susceptible (PBL-S) but piperacillin-tazobactam resistant (TZP-R) in vitro. We assessed the in vivo significance of this resistance profile in a neutropenic murine pneumonia model using humanized exposures of TZP with 18 clinical E. coli isolates, 8 TZP-S/PBL-S and 10 genotypically confirmed TZPR/PBL-S. Despite phenotypically and genotypically defined resistance, TZP displayed efficacy against these isolates. Additional studies are required to define the clinical implications of these TZP-R/PBL-S strains.

引用

页码：7527 / 7529

页数：3

共 16 条

[1] BEAM TR, 1983, J MED, V14, P307
[2] In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms
Bulik, Catharine C.
Tessier, Pamela R.
Keel, Rebecca A.
Sutherland, Christina A.
Nicolaua, David P.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) : 544 - 549
[3] Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Bulik, Catharine C.
Nicolau, David P.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (06) : 3002 - 3004
[4] In Vivo Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase-Producing Klebsiella pneumoniae
Bulik, Catharine C.
Nicolau, David P.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4112 - 4115
[5] Comparison of the Activity of a Human Simulated, High-Dose, Prolonged Infusion of Meropenem against Klebsiella pneumoniae Producing the KPC Carbapenemase versus That against Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model
Bulik, Catharine C.
Christensen, Henry
Li, Peng
Sutherland, Christina A.
Nicolau, David P.
Kuti, Joseph L.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (02) : 804 - 810
[6] Clinical and Laboratory Standards Institute, 2016, M100S25 CLSI
[7] Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
Coleman, Ken
Levasseur, Premavathy
Girard, Anne-Marie
Borgonovi, Monica
Miossec, Christine
Merdjan, Henri
Drusano, George
Shlaes, David
Nichols, Wright W.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) : 3366 - 3372
[8] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
Craig, WA
[J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
[9] Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
Crandon, Jared L.
Schuck, Virna J.
Banevicius, Mary Anne
Beaudoin, Marie-Eve
Nichols, Wright W.
Tanudra, M. Angela
Nicolau, David P.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (12) : 6137 - 6146
[10] Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality
Diaz-Martin, Ana
Luisa Martinez-Gonzalez, Maria
Ferrer, Ricard
Ortiz-Leyba, Carlos
Piacentini, Enrique
Jesus Lopez-Pueyo, Maria
Martin-Loeches, Ignacio
Levy, Mitchell M.
Artigas, Antoni
Garnacho-Montero, Jose
[J]. CRITICAL CARE, 2012, 16 (06)

← 1 2 →